Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

OxyContin Repeat? US FDA Seeks To Avoid Fallout Over Butrans Pediatric Data

Sep 13 2017

• By Sue Sutter

Related Content

Opioids Can't Stop Califf Confirmation

Feb 23 2016

FDA Opioid Action Plan Means More Advisory Committees And A New Look At REMS, PMRs

Feb 16 2016

Pediatric Opioid Development Faces Grim Outlook After Advisory Cmte.

Sep 20 2016

FDA's Opioid Regret? Skipping Another Zohydro Meeting, Califf Says

Mar 03 2016

Keeping Track: Neurology And Pain Products Keep FDA Occupied

Aug 17 2015

Opioid Cough Restrictions: Pediatric Use, And Postmarket Studies, Likely Limited

Sep 12 2017

Purdue's Butrans: US FDA Panel To Consider Pediatric Labeling, But Not A New Indication

Aug 16 2017

Related Companies

Purdue Pharma L.P.

Additional Topics

United States Advisory Committees Pediatrics Post Market Regulation & Studies Drug Review Regulation BioPharmaceutical Neurology

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window